| Autor: |
Carsote M; Department of Endocrinology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Clinical Endocrinology V, 'C.I. Parhon' National Institute of Endocrinology, 011863 Bucharest, Romania., Nistor C; Department 4-Cardio-Thoracic Pathology, Thoracic Surgery II Discipline, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania.; Thoracic Surgery Department, 'Dr. Carol Davila' Central Military University Emergency Hospital, 010242 Bucharest, Romania., Gheorghe AM; PhD Doctoral School, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania., Sima OC; PhD Doctoral School, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania., Trandafir AI; PhD Doctoral School, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania., Nistor TVI; Department of Clinical Biochemistry, 'Iuliu Hatieganu' University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania., Sandulescu BA; PhD Doctoral School, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Internal Medicine and Gastroenterology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Internal Medicine I and Rheumatology, 'Dr. Carol Davila' Central Military University Emergency Hospital, 010825 Bucharest, Romania., Ciobica ML; Department of Internal Medicine and Gastroenterology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Internal Medicine I and Rheumatology, 'Dr. Carol Davila' Central Military University Emergency Hospital, 010825 Bucharest, Romania. |
| Abstrakt: |
We aimed to provide an in-depth analysis with respect to three turning points in pancreas involvement in primary hyperparathyroidism (PHP): hypercalcemia-induced pancreatitis (HCa-P), MEN1 (multiple endocrine neoplasia)-related neuroendocrine tumors (NETs), and insulin resistance (IR). This was a comprehensive review conducted via a PubMed search between January 2020 and January 2024. HCa-P ( n = 9 studies, N = 1375) involved as a starting point parathyroid NETs ( n = 7) or pancreatitis ( n = 2, N = 167). Case report-focused analysis (N = 27) showed five cases of pregnancy PHP-HCa-P and three reports of parathyroid carcinoma (female/male ratio of 2/1, ages of 34 in women, men of 56). MEN1-NET studies ( n = 7) included MEN1-related insulinomas ( n = 2) or MEN1-associated PHP ( n = 2) or analyses of genetic profile ( n = 3), for a total of 877 MEN1 subjects. In MEN1 insulinomas (N = 77), the rate of associated PHP was 78%. Recurrence after parathyroidectomy (N = 585 with PHP) was higher after less-than-subtotal versus subtotal parathyroidectomy (68% versus 45%, p < 0.001); re-do surgery was 26% depending on surgery for pancreatic NETs (found in 82% of PHP patients). MEN1 pathogenic variants in exon 10 represented an independent risk factor for PHP recurrence. A single pediatric study in MEN1 (N = 80) revealed the following: a PHP rate of 80% and pancreatic NET rate of 35% and 35 underlying germline MEN1 pathogenic variants (and 3/35 of them were newly detected). The co-occurrence of genetic anomalies included the following: CDC73 gene variant, glucokinase regulatory protein gene pathogenic variant (c.151C>T, p.Arg51*), and CAH-X syndrome. IR/metabolic feature-focused analysis identified ( n = 10, N = 1010) a heterogeneous spectrum: approximately one-third of adults might have had prediabetes, almost half displayed some level of IR as reflected by HOMA-IR > 2.6, and serum calcium was positively correlated with HOMA-IR. Vitamin D deficiency was associated with a higher rate of metabolic syndrome ( n = 1). Normocalcemic and mildly symptomatic hyperparathyroidism ( n = 6, N = 193) was associated with a higher fasting glucose and some improvement after parathyroidectomy. This multilayer pancreas/parathyroid analysis highlighted a complex panel of connections from pathogenic factors, including biochemical, molecular, genetic, and metabolic factors, to a clinical multidisciplinary panel. |
